ASEANのポイントオブケア診断市場 – 2030年までの予測

ASEAN Point of Care Diagnostics Market - Forecast to 2030

ASEANのポイントオブケア診断市場 - 製品(感染症(結核、肝炎、性感染症、院内感染)、グルコース、心血管代謝、妊娠、凝固)、技術(ラテラルフローアッセイ、生化学、MDx)、エンドユーザー(在宅ケア、病院) - 2030年までの予測
ASEAN Point of Care Diagnostics Market by Product (Infectious Disease (TB, Hepatitis, STDs, HAIs), Glucose, Cardiometabolic, Pregnancy, Coagulation), Technology (Lateral Flow Assays, Biochemistry, MDx), End User (Home Care, Hospitals) - Forecast to 2030

商品番号 : SMB-8956

出版社MarketsandMarkets
出版年月2025年5月
ページ数334
図表数319
価格タイプシングルユーザライセンス
価格USD 4,950
種別英文調査報告書

この調査レポートでは、ASEANのPOC診断市場を製品別(感染症検査製品、血糖値モニタリング製品、心血管代謝検査製品、凝固モニタリング製品、妊娠・妊孕性検査製品、尿検査製品、がんマーカー検査製品、コレステロール検査製品、血液学検査製品、便潜血検査製品、乱用薬物検査製品、その他POC製品)、技術別(ラテラルフローアッセイ(免疫測定)、迅速検査(分子診断)、生化学)、エンドユーザー別(臨床検査室、病院および救命救急センター、外来診療所および外来診療センター、在宅ケア施設、その他エンドユーザー)、国別(ベトナム、ラオス、カンボジア、マレーシア、ミャンマー、フィリピン、シンガポール、タイ、インドネシア、ブルネイ)に分類しています。レポートは、ASEANのPOC診断市場の成長に影響を与える主要要因(促進要因、抑制要因、機会、課題など)に関する包括的な情報を提供しています。本レポートでは、主要業界プレーヤーの詳細な分析を掲載し、事業概要、ソリューション、主要戦略、買収、契約に関する洞察を提供しています。さらに、新製品・新サービスの発売、そしてポイントオブケア診断市場の最新動向についても解説しています。さらに、ASEANのポイントオブケア診断エコシステムにおける新興スタートアップ企業の競合分析も含まれています。

The ASEAN point of care diagnostics market is expected to grow from USD 1.08 billion in 2025 to reach USD 1.36 billion in 2030, at a CAGR of 4.7% during the forecast period.

ASEANのポイントオブケア診断市場は、予測期間中に4.7%のCAGRで成長し、2025年の10億8,000万米ドルから2030年には13億6,000万米ドルに達すると予想されています。

ASEANのポイントオブケア診断市場 - 2030年までの予測
asean-north-asian-point-care-rapid-diagnostics-market-Overview

Favorable government policies and funding investments drive the demand for Point of Care (POC) testing in the ASEAN region. Governments in these countries are increasingly supporting adopting such technologies to improve health access, reduce costs, and enhance patient outcomes. Through strategic partnerships, research initiatives, and nationwide screening campaigns, ASEAN governments promote using POC technologies to make healthcare accessible, lower costs, and improve patient outcomes. In several developing nations within the region, where health infrastructure is relatively underdeveloped, authorities encourage using POC devices to decentralize laboratory-based diagnostics and expand access to testing. These supportive initiatives are fostering the growth of POC diagnostics and creating new market opportunities for diagnostic firms in the ASEAN region.

ASEAN地域におけるPOC(Point of Care)検査の需要は、政府の好ましい政策と資金投資によって牽引されています。これらの国々の政府は、医療へのアクセス向上、コスト削減、そして患者アウトカムの向上を目指し、こうした技術の導入をますます支援しています。ASEAN諸国政府は、戦略的パートナーシップ、研究イニシアチブ、そして全国規模のスクリーニングキャンペーンを通じて、POC技術の活用を促進し、医療へのアクセス向上、コスト削減、そして患者アウトカムの向上を目指しています。医療インフラが比較的未整備なASEAN地域の発展途上国では、当局がPOC機器の活用を奨励し、臨床検査による診断を分散化し、検査へのアクセスを拡大しています。こうした支援策はPOC診断の成長を促進し、ASEAN地域の診断企業にとって新たな市場機会を創出しています。

“The infectious disease testing products segment is expected to register the highest growth rate in the ASEAN point of care diagnostics market, by product.”

Based on product, the ASEAN point of care diagnostics market is segmented into infectious disease testing products, glucose monitoring products, cardiometabolic testing products, coagulation monitoring products, pregnancy & fertility testing products, urinalysis testing products, cancer marker testing products, cholesterol testing products, hematology testing products, fecal occult testing products, drugs-of-abuse testing products, and other POC products. Among them, the infectious disease testing products segment is expected to grow at the highest CAGR, primarily driven by the region’s continuous efforts towards enhancing disease surveillance and outbreak control. Recurrent outbreaks of infectious diseases, in addition to the requirement for rapid diagnosis in both urban & rural healthcare facilities, are fueling the demand for effective POC solutions. Additionally, the rapid development of advanced molecular platforms and immunoassays will facilitate the effective and smooth identification of infectious diseases, further expanding adoption among ASEAN countries.

“By technology, the Biochemistry segment accounted for the largest market share in the ASEAN point of care diagnostics market in 2024.”

The ASEAN point of care diagnostics market is segmented by technology into lateral flow assays (immunoassays), rapid tests (molecular diagnostics), and biochemistry. In 2024, the Biochemistry segment accounted for the largest share of the market owing to its extensive usability in a variety of routine & essential diagnostic tests such as blood glucose checks, electrolyte analysis, liver function tests, and kidney function tests. The high prevalence of chronic & lifestyle-associated diseases like diabetes, cardiovascular disease, and kidney disorders in the ASEAN countries has also substantially necessitated the need for point-of-care testing solutions based on biochemistry. Moreover, the ease of operation, cost-effectiveness, and shorter turnaround time of biochemistry analyzers make them appropriate for decentralized healthcare environments such as community clinics, primary health centers, and emergency departments. The growing demand for early disease detection & diagnosis has further supported the implementation of biochemistry-based POC solutions in the ASEAN market.

“Vietnam is the fastest-growing market for point of care diagnostics in the ASEAN region”

The ASEAN market for point of care diagnostics is categorized into Vietnam, Laos, Cambodia, Malaysia, Myanmar, Philippines, Singapore, Thailand, Indonesia, and Brunei. Vietnam is expected to grow at the highest CAGR during the forecast period. Vietnam’s strong focus on strengthening its primary healthcare network and expanding nationwide screening programs—especially after the COVID-19 pandemic—has significantly increased the adoption of point-of-care diagnostic solutions in public and private healthcare facilities. Additionally, the country is committed to improving the early detection and management of infectious diseases, bolstered by its robust disease surveillance and monitoring systems, which will support long-term market growth. As reflected in its Joint External Evaluation and Global Health Security Index scores, Vietnam’s impressive performance in global health security indicators highlights the healthcare system’s growing capacity to implement point-of-care diagnostics in the coming years.

The break-up of the profile of primary participants in the ASEAN point of care diagnostics market:

  • By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
  • By Designation: C-level – 27%, D-level – 18%, and Others – 55%

The key players in this market are Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), Danaher Corporation (US), BD (US), QuidelOrtho Corporation (US), Cardinal Health (US), AccuBioTech Co., Ltd. (China), EKF Diagnostics Holdings plc (UK), bioMérieux (France), Thermo Fisher Scientific Inc. (US), BIOSYNEX SA (France), PTS Diagnostics (US), LifeScan IP Holdings, LLC (US), SD Biosensor, INC. (South Korea), CTK Biotech, Inc. (US), Wondfo (China), Trinity Biotech (Ireland), SEKISUI Diagnostics (US), Werfen (Spain), ARKRAY, Inc. (US), Xiamen Boson Biotech Co., Ltd. (China), Credo Diagnostics Biomedical Pte. Ltd. (Singapore), Anbio Biotechnology Inc. (Germany), and SG Diagnostics (Singapore).

ASEANのポイントオブケア診断市場 - 2030年までの予測 ecosystem
asean-north-asian-point-care-rapid-diagnostics-market-Ecosystem

Research Coverage:

This research report categorizes the ASEAN point of care diagnostics market by product (infectious disease testing products, glucose monitoring products, cardiometabolic testing products, coagulation monitoring products, pregnancy & fertility testing products, urinalysis testing products, cancer marker testing products, cholesterol testing products, hematology testing products, fecal occult testing products, drugs-of-abuse testing products, and other POC products),  by technology [lateral flow assays (immunoassays), rapid tests (molecular diagnostics), and biochemistry], by end user (clinical laboratories, hospitals and critical care centers, outpatient settings and ambulatory care centers, home care settings,  and other end users) and by country (Vietnam, Laos, Cambodia, Malaysia, Myanmar, Philippines, Singapore, Thailand, Indonesia, and Brunei). The report provides comprehensive information on the key factors influencing the growth of the ASEAN point-of-care diagnostics market, including drivers, restraints, opportunities, and challenges. It includes a detailed analysis of the major industry players, offering insights into their business overviews, solutions, key strategies, acquisitions, and agreements. Additionally, the report discusses new product and service launches and recent developments in the point-of-care diagnostics market. A competitive analysis of emerging startups within the ASEAN point-of-care diagnostics ecosystem is also included.

Reasons to buy this report:

The report will help market leaders and new entrants with information on the closest approximations of the revenue numbers for the ASEAN point of care diagnostics market and its subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following points:

  • Analysis of key drivers [Rising incidence of infectious diseases, increasing prevalence of chronic diseases, favorable government initiatives for POC testing, and the rising number of Public-Private Partnerships (PPPs)], opportunities (Gradual shift toward decentralized healthcare systems and availability of POC tests with multiplexing capabilities), restraints (Pricing pressure on manufacturers and stringent regulatory approval process for product commercialization), and challenges (Shortage of skilled healthcare providers and premium pricing of novel platforms) that influence the growth of the ASEAN point of care diagnostics market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the ASEAN point of care diagnostics market.
  • Market Development: Comprehensive information about lucrative markets—the report analyses the ASEAN point of care diagnostics market across various countries.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the ASEAN point of care diagnostics market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), and Danaher Corporation (US).

Table of Contents

1               INTRODUCTION              27

1.1           STUDY OBJECTIVES       27

1.2           MARKET DEFINITION   27

1.3           STUDY SCOPE   28

1.3.1        MARKET SCOPE                28

1.3.2        INCLUSIONS & EXCLUSIONS       29

1.3.3        YEARS CONSIDERED      30

1.3.4        CURRENCY CONSIDERED            30

1.4           KEY STAKEHOLDERS     30

1.5           SUMMARY OF CHANGES               30

2               RESEARCH METHODOLOGY       32

2.1           RESEARCH DATA              32

2.1.1        SECONDARY DATA          32

2.1.1.1    Key secondary sources         33

2.1.1.2    Key data from secondary sources       33

2.1.1.3    Key objectives       34

2.1.2        PRIMARY DATA 34

2.1.2.1    Key primary sources             35

2.1.2.2    Key data from primary sources           35

2.1.2.3    Key industry insights           37

2.2           MARKET SIZE ESTIMATION         38

2.2.1        BOTTOM-UP APPROACH              39

2.2.1.1    Company revenue estimation approach            39

2.2.1.2    Presentations of companies & primary interviews           39

2.2.1.3    Growth forecast    40

2.2.1.4    CAGR projections                 40

2.2.2        TOP-DOWN APPROACH                40

2.3           DATA TRIANGULATION                42

2.4           MARKET SHARE ANALYSIS           43

2.5           RESEARCH ASSUMPTIONS           43

2.5.1        GROWTH RATE ASSUMPTIONS 43

2.6           RESEARCH LIMITATIONS             44

2.7           RISK ASSESSMENT           44

3               EXECUTIVE SUMMARY  45

4               PREMIUM INSIGHTS       49

4.1           ASEAN POINT OF CARE DIAGNOSTICS MARKET OVERVIEW          49

4.2           ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2030                50

4.3           ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030       50

4.4           ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030          51

4.5           ASEAN POINT OF CARE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES            51

5               MARKET OVERVIEW       52

5.1           INTRODUCTION              52

5.2           MARKET DYNAMICS       52

5.2.1        DRIVERS               53

5.2.1.1    Rising incidence of infectious diseases              53

5.2.1.2    Increasing prevalence of chronic diseases        55

5.2.1.3    Favorable government initiatives for POC testing          57

5.2.1.4    Rising number of public-private partnerships (PPPs)   58

5.2.2        RESTRAINTS      58

5.2.2.1    Pricing pressure on manufacturers    58

5.2.2.2    Stringent regulatory approval process for product commercialization                 59

5.2.3        OPPORTUNITIES              59

5.2.3.1    Gradual shift toward decentralized healthcare systems 59

5.2.3.2    Availability of POC tests with multiplexing capabilities 60

5.2.4        CHALLENGES    60

5.2.4.1    Shortage of skilled healthcare providers            60

5.2.4.2    Premium pricing of novel platforms 61

5.3           TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES       61

5.4           PRICING ANALYSIS          62

5.4.1        INDICATIVE SELLING PRICE TREND OF POC TESTS, BY PRODUCT           62

5.4.2        INDICATIVE SELLING PRICE TREND OF GLUCOSE TEST STRIPS, BY KEY PLAYER 63

5.4.3        INDICATIVE SELLING PRICE TREND OF POC PREGNANCY TEST KITS,

BY COUNTRY     63

5.5           VALUE CHAIN ANALYSIS               64

5.6           SUPPLY CHAIN ANALYSIS             65

5.7           ECOSYSTEM ANALYSIS  66

5.8           INVESTMENT & FUNDING SCENARIO     68

5.9           TECHNOLOGY ANALYSIS             68

5.9.1        KEY TECHNOLOGIES     68

5.9.1.1    Lateral flow assays                68

5.9.2        COMPLEMENTARY TECHNOLOGIES       69

5.9.2.1    Molecular diagnostics          69

5.9.3        ADJACENT TECHNOLOGIES       70

5.9.3.1    Biochemical technologies    70

5.10         PATENT ANALYSIS          71

5.11         TRADE ANALYSIS             73

5.11.1      IMPORT DATA FOR HS CODE 3822            73

5.11.2      EXPORT DATA FOR HS CODE 3822            74

5.12         KEY CONFERENCES & EVENTS, 2025–2026              74

5.13         REGULATORY ANALYSIS               76

5.13.1      REGULATORY LANDSCAPE         76

5.13.1.1  Vietnam 76

5.13.1.2  Laos        76

5.13.1.3  Cambodia               77

5.13.1.4  Malaysia 77

5.13.1.5  Myanmar                78

5.13.1.6  Philippines             78

5.13.1.7  Singapore               79

5.13.1.8  Thailand 79

5.13.1.9  Indonesia                80

5.13.1.10                 Brunei    80

5.13.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             80

5.14         PORTER’S FIVE FORCES ANALYSIS           82

5.14.1      THREAT OF NEW ENTRANTS      83

5.14.2      THREAT OF SUBSTITUTES          83

5.14.3      BARGAINING POWER OF BUYERS             83

5.14.4      BARGAINING POWER OF SUPPLIERS       83

5.14.5      INTENSITY OF COMPETITIVE RIVALRY 84

5.15         KEY STAKEHOLDERS & BUYING CRITERIA            84

5.15.1      KEY STAKEHOLDERS IN BUYING PROCESS           84

5.15.2      KEY BUYING CRITERIA  85

5.16         IMPACT OF AI ON ASEAN POINT OF CARE DIAGNOSTICS MARKET               85

5.16.1      INTRODUCTION              85

5.16.2      MARKET POTENTIAL OF AI IN POC DIAGNOSTIC APPLICATIONS 86

5.16.3      AI USE CASES     86

5.16.4      KEY COMPANIES IMPLEMENTING AI      87

5.16.5      FUTURE OF AI IN ASEAN POINT OF CARE DIAGNOSTICS MARKET               88

6               ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT           89

6.1           INTRODUCTION              90

6.2           GLUCOSE MONITORING PRODUCTS      91

6.2.1        GLUCOMETERS                 93

6.2.1.1    Accurate monitoring of blood sugar levels to drive market                 93

6.2.2        GLUCOSE TEST STRIPS 95

6.2.2.1    Increasing uptake of single-use products to fuel market                 95

6.2.3        LANCETS             97

6.2.3.1    Increasing preference for home-based care to support market growth    97

6.3           INFECTIOUS DISEASE TESTING PRODUCTS        98

6.3.1        RESPIRATORY INFECTION TESTING PRODUCTS                 100

6.3.1.1    TB testing products              102

6.3.1.1.1 High prevalence of tuberculosis cases to fuel market     102

6.3.1.2    Influenza testing products  103

6.3.1.2.1 Rising need for targeted treatment therapies to boost demand                 103

6.3.1.3    Other respiratory infection testing products   105

6.3.2        MOSQUITO-BORNE DISEASE TESTING PRODUCTS                 107

6.3.2.1    Rising incidence of malaria & dengue to boost demand 107

6.3.3        STD TESTING PRODUCTS            109

6.3.3.1    Need to reduce disease transmission rates to facilitate growth                 109

6.3.4        HIV TESTING PRODUCTS             111

6.3.4.1    Growing awareness of HIV POC testing to boost demand                 111

6.3.5        HAI TESTING PRODUCTS             114

6.3.5.1    Growing incidence of HAIs in healthcare settings to drive market                 114

6.3.6        HEPATITIS TESTING PRODUCTS              116

6.3.6.1    Hepatitis B testing products               117

6.3.6.1.1 Increasing prevalence of liver infections to fuel market 117

6.3.6.2    Hepatitis C testing products               119

6.3.6.2.1 Rising need to combat hepatitis among high-risk subgroups to support market growth        119

6.3.7        OTHER INFECTIOUS DISEASE TESTING PRODUCTS                 121

6.4           COVID-19 TESTING PRODUCTS 123

6.4.1        GRADUAL SHIFT TOWARDS SYNDROMIC TESTING TO SUPPORT MARKET GROWTH     123

6.5           CARDIOMETABOLIC TESTING PRODUCTS           125

6.5.1        CARDIAC MARKER TESTING PRODUCTS               128

6.5.1.1    Early detection of myocardial infarctions and acute coronary syndromes to fuel market    128

6.5.2        HBA1C TESTING PRODUCTS      129

6.5.2.1    Provision of long-term measurement in blood glucose control to boost demand        129

6.5.3        BLOOD GAS & ELECTROLYTE TESTING PRODUCTS                 130

6.5.3.1    Monitoring of key parameters for pH and oxygen saturation to drive market          130

6.6           COAGULATION MONITORING PRODUCTS          131

6.6.1        HIGH INCIDENCE OF BLEEDING DISORDERS TO FUEL UPTAKE                131

6.7           PREGNANCY & FERTILITY TESTING PRODUCTS                 133

6.7.1        GROWING AWARENESS OF SUSTAINABLE FAMILY PLANNING TO PROPEL MARKET               133

6.8           HEMATOLOGY TESTING PRODUCTS      136

6.8.1        RISING DEMAND FOR BLOOD TRANSFUSION PROCEDURES TO DRIVE MARKET            136

6.9           CANCER MARKER TESTING PRODUCTS 138

6.9.1        INCREASING PREFERENCE FOR PERSONALIZED ONCOLOGY THERAPEUTICS TO PROPEL MARKET           138

6.10         FECAL OCCULT TESTING PRODUCTS    141

6.10.1      FAVORABLE INITIATIVES FOR COLORECTAL CANCER SCREENING TO BOOST MARKET               141

6.11         CHOLESTEROL TESTING PRODUCTS     143

6.11.1      RISING OBESITY RATE CAUSED BY SEDENTARY LIFESTYLES TO DRIVE MARKET                 143

6.12         URINALYSIS TESTING PRODUCTS            145

6.12.1      RISING PREVALENCE OF UTIS AND KIDNEY DISEASES TO DRIVE MARKET         145

6.13         DRUGS-OF-ABUSE TESTING PRODUCTS               147

6.13.1      HIGH CONSUMPTION OF ILLICIT DRUGS TO FUEL MARKET               147

6.14         OTHER POC PRODUCTS               149

7               ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY  151

7.1           INTRODUCTION              152

7.2           BIOCHEMISTRY                152

7.2.1        PROVISION OF RAPID ONSITE RESULTS FOR CHRONIC CONDITIONS TO DRIVE MARKET             152

7.3           LATERAL FLOW ASSAYS (IMMUNOASSAYS)         154

7.3.1        INTEGRATION OF ELISA INTO DISPOSABLE TESTING STRIPS FOR COMPLEX LABORATORY ANALYSIS TO FUEL MARKET               154

7.4           RAPID TESTS (MOLECULAR DIAGNOSTICS)        157

7.4.1        ANALYSIS OF BIOLOGICAL MARKERS FOR RAPID DISEASE DETECTION TO PROPEL MARKET         157

8               ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER     159

8.1           INTRODUCTION              160

8.2           HOME CARE SETTINGS 160

8.2.1        GROWING CONSUMER PREFERENCE FOR CONVENIENCE AND AFFORDABILITY TO PROPEL MARKET                 160

8.3           CLINICAL LABORATORIES           162

8.3.1        MANAGEMENT OF HIGH PATIENT VOLUMES WITH AUTOMATED TESTING SOLUTIONS TO FUEL MARKET 162

8.4           HOSPITALS AND CRITICAL CARE CENTERS         163

8.4.1        RISING REQUIREMENT FOR RAPID POC TESTING IN EMERGENCY USE TO SUPPORT MARKET GROWTH          163

8.5           OUTPATIENT SETTINGS AND AMBULATORY CARE CENTERS             165

8.5.1        COST-EFFECTIVENESS OVER HOSPITALS TO BOOST MARKET GROWTH          165

8.6           OTHER END USERS         166

9               ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY            168

9.1           INTRODUCTION              169

9.1.1        MACROECONOMIC OUTLOOK FOR ASEAN COUNTRIES                 171

9.2           INDONESIA        172

9.2.1        RISING PUBLIC AWARENESS ABOUT PREVENTIVE HEALTHCARE TO DRIVE MARKET            172

9.2.2        MACROECONOMIC OUTLOOK FOR INDONESIA                 173

9.3           THAILAND          178

9.3.1        EXPANDING GERIATRIC POPULATION AND SUBSEQUENT RISE IN CHRONIC DISEASES TO FUEL MARKET                 178

9.3.2        MACROECONOMIC OUTLOOK FOR THAILAND 179

9.4           MALAYSIA           184

9.4.1        HIGH INCIDENCE OF DIABETES TO BOOST DEMAND                 184

9.4.2        MACROECONOMIC OUTLOOK FOR MALAYSIA  185

9.5           PHILIPPINES      190

9.5.1        IMPROVED HEALTHCARE ACCESS AND INSURANCE COVERAGE TO FUEL ADOPTION              190

9.5.2        MACROECONOMIC OUTLOOK FOR PHILIPPINES                 191

9.6           VIETNAM             196

9.6.1        IMPROVING HEALTHCARE INFRASTRUCTURE AND FAVORABLE GOVERNMENT INITIATIVES TO PROPEL MARKET                 196

9.6.2        MACROECONOMIC OUTLOOK FOR VIETNAM    197

9.7           SINGAPORE        202

9.7.1        INCREASING DEMAND FOR SPECIALIZED MEDICAL SERVICES TO BOOST MARKET   202

9.7.2        MACROECONOMIC OUTLOOK FOR SINGAPORE                 203

9.8           MYANMAR           208

9.8.1        RISING NEED FOR AFFORDABLE DIAGNOSTIC SOLUTIONS TO DRIVE MARKET                208

9.8.2        MACROECONOMIC OUTLOOK FOR MYANMAR 209

9.9           CAMBODIA         214

9.9.1        RISING PREVALENCE OF NCDS TO SUPPORT MARKET GROWTH             214

9.9.2        MACROECONOMIC OUTLOOK FOR CAMBODIA                 215

9.10         LAOS     220

9.10.1      NEED FOR DECENTRALIZED DIAGNOSTIC SOLUTIONS TO FUEL DEMAND          220

9.10.2      MACROECONOMIC OUTLOOK FOR LAOS             221

9.11         BRUNEI 226

9.11.1      GROWING NEED FOR COST-EFFECTIVE POC SOLUTIONS TO FUEL MARKET  226

9.11.2      MACROECONOMIC OUTLOOK FOR BRUNEI       227

10            COMPETITIVE LANDSCAPE         233

10.1         INTRODUCTION              233

10.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            233

10.2.1      OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ASEAN POINT OF CARE DIAGNOSTICS MARKET                 234

10.3         REVENUE ANALYSIS, 2022–2024  236

10.4         MARKET SHARE ANALYSIS, 2024                 237

10.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 238

10.5.1      STARS   239

10.5.2      EMERGING LEADERS     239

10.5.3      PERVASIVE PLAYERS      239

10.5.4      PARTICIPANTS 239

10.5.5      COMPANY FOOTPRINT, KEY PLAYERS, 2024         241

10.5.5.1  Company footprint               241

10.5.5.2  Country footprint 242

10.5.5.3  Product footprint  243

10.5.5.4  Technology footprint           245

10.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        246

10.6.1      PROGRESSIVE COMPANIES         246

10.6.2      RESPONSIVE COMPANIES            246

10.6.3      DYNAMIC COMPANIES  246

10.6.4      STARTING BLOCKS         246

10.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 248

10.6.5.1  Detailed list of key startups/SMEs    248

10.6.5.2  Competitive benchmarking of key startups/SMEs, by technology                 248

10.6.5.3  Competitive benchmarking of key startups/SMEs, by country                 249

10.7         COMPANY VALUATION & FINANCIAL METRICS 249

10.7.1      FINANCIAL METRICS      249

10.7.2      COMPANY VALUATION 250

10.8         BRAND/PRODUCT COMPARISON             250

10.9         COMPETITIVE SCENARIO             251

10.9.1      PRODUCT LAUNCHES & APPROVALS     251

10.9.2      DEALS  252

10.9.3      EXPANSIONS     253

11            COMPANY PROFILES      254

11.1         KEY PLAYERS     254

11.1.1      ABBOTT               254

11.1.1.1  Business overview 254

11.1.1.2  Products offered   255

11.1.1.3  Recent developments           258

11.1.1.3.1                Product approvals 258

11.1.1.3.2                Deals      258

11.1.1.4  MnM view              259

11.1.1.4.1                Key strengths        259

11.1.1.4.2                Strategic choices   259

11.1.1.4.3                Weaknesses & competitive threats     259

11.1.2      F. HOFFMANN-LA ROCHE LTD. 260

11.1.2.1  Business overview 260

11.1.2.2  Products offered   261

11.1.2.3  Recent developments           263

11.1.2.3.1                Product launches & approvals            263

11.1.2.3.2                Deals      264

11.1.2.4  MnM view              265

11.1.2.4.1                Key strengths        265

11.1.2.4.2                Strategic choices   265

11.1.2.4.3                Weaknesses & competitive threats     265

11.1.3      SIEMENS HEALTHINEERS AG      266

11.1.3.1  Business overview 266

11.1.3.2  Products offered   267

11.1.3.3  Recent developments           269

11.1.3.3.1                Product approvals 269

11.1.3.3.2                Deals      269

11.1.3.3.3                Expansions             271

11.1.3.4  MnM view              271

11.1.3.4.1                Key strengths        271

11.1.3.4.2                Strategic choices   271

11.1.3.4.3                Weaknesses & competitive threats     271

11.1.4      SYSMEX CORPORATION                272

11.1.4.1  Business overview 272

11.1.4.2  Products offered   273

11.1.4.3  Recent developments           274

11.1.4.3.1                Expansions             274

11.1.4.4  MnM view              274

11.1.4.4.1                Key strengths        274

11.1.4.4.2                Strategic choices   274

11.1.4.4.3                Weaknesses & competitive threats     275

11.1.5      DANAHER CORPORATION           276

11.1.5.1  Business overview 276

11.1.5.2  Products offered   277

11.1.5.3  MnM view              278

11.1.5.3.1                Key strengths        278

11.1.5.3.2                Strategic choices   279

11.1.5.3.3                Weaknesses and competitive threats 279

11.1.6      BD          280

11.1.6.1  Business overview 280

11.1.6.2  Products offered   281

11.1.6.3  Recent developments           282

11.1.6.3.1                Deals      282

11.1.6.3.2                Expansions             282

11.1.7      QUIDELORTHO CORPORATION                283

11.1.7.1  Business overview 283

11.1.7.2  Recent developments           287

11.1.7.2.1                Product approvals 287

11.1.7.2.2                Deals      288

11.1.7.2.3                Expansions             290

11.1.8      CARDINAL HEALTH        291

11.1.8.1  Business overview 291

11.1.8.2  Products offered   292

11.1.8.3  Recent developments           293

11.1.8.3.1                Deals      293

11.1.8.3.2                Expansions             294

11.1.9      BIOMÉRIEUX     295

11.1.9.1  Business overview 295

11.1.9.2  Products offered   296

11.1.9.3  Recent developments           297

11.1.9.3.1                Product approvals 297

11.1.9.3.2                Deals      298

11.1.10   EKF DIAGNOSTICS HOLDINGS PLC          299

11.1.10.1                 Business overview 299

11.1.10.2                 Products offered   300

11.1.10.3                 Recent developments           301

11.1.10.3.1             Product launches  301

11.1.10.3.2             Deals      301

11.1.10.3.3             Expansions             301

11.1.11   THERMO FISHER SCIENTIFIC INC.            302

11.1.11.1                 Business overview 302

11.1.11.2                 Products offered   303

11.1.11.3                 Recent developments           304

11.1.11.3.1             Product launches  304

11.1.11.3.2             Deals      304

11.1.12   ACCUBIOTECH, CO., LTD.            305

11.1.12.1                 Business overview 305

11.1.12.2                 Products offered   305

11.1.12.3                 Recent developments           307

11.1.12.3.1             Product approvals 307

11.2         OTHER PLAYERS              308

11.2.1      BIOSYNEX SA     308

11.2.2      SD BIOSENSOR, INC.       309

11.2.3      SEKISUI DIAGNOSTICS  311

11.2.4      WERFEN               312

11.2.5      TRINITY BIOTECH           313

11.2.6      PTS DIAGNOSTICS          314

11.2.7      LIFESCAN IP HOLDINGS, LLC     315

11.2.8      CTK BIOTECH, INC.         316

11.2.9      WONDFO             318

11.2.10   ARKRAY, INC.     319

11.2.11   XIAMEN BOSON BIOTECH CO., LTD.       320

11.2.12   CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD.  322

11.2.13   ANBIO BIOTECHNOLOGY INC.  323

11.2.14   SG DIAGNOSTICS             325

12            APPENDIX           326

12.1         DISCUSSION GUIDE        326

12.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                330

12.3         AVAILABLE CUSTOMIZATIONS 332

12.4         RELATED REPORTS         332

12.5         AUTHOR DETAILS           333

LIST OF TABLES

TABLE 1                ASEAN POINT OF CARE DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES     35

TABLE 2                ASEAN POINT OF CARE DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS      44

TABLE 3                HEPATITIS DISEASE BURDEN AND DEATHS CAUSED BY HEPATITIS, BY COUNTRY (2022)       54

TABLE 4                DIABETES ESTIMATES (AGES 20–79) AND DIABETES-RELATED DEATHS,

BY COUNTRY, 2021           56

TABLE 5                PROJECTED INCREASE IN CANCER PATIENTS, BY COUNTRY,

2022 VS. 2035 VS. 2045      56

TABLE 6                INDICATIVE SELLING PRICE TREND OF POC TESTS, BY PRODUCT, 2023–2025                 62

TABLE 7                INDICATIVE SELLING PRICE TREND OF GLUCOSE TEST STRIPS, BY KEY PLAYER, 2023−2025         63

TABLE 8                INDICATIVE SELLING PRICE TREND OF POC PREGNANCY TEST KITS, BY COUNTRY, 2023–2025              63

TABLE 9                ASEAN POINT OF CARE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM     67

TABLE 10              ASEAN POINT OF CARE DIAGNOSTICS MARKET: INNOVATIONS & PATENT REGISTRATIONS, 2022–2024    72

TABLE 11              IMPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822),

BY COUNTRY, 2020–2024 (USD THOUSAND)         73

TABLE 12              EXPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822),

BY COUNTRY, 2020–2024 (USD THOUSAND)         74

TABLE 13              ASEAN POC DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2025–2026       74

TABLE 14              MALAYSIA: CLASSIFICATION OF IVD MEDICAL DEVICES              77

TABLE 15              MYANMAR: CLASSIFICATION OF IVD MEDICAL DEVICES              78

TABLE 16              ASEAN COUNTRIES: KEY REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  80

TABLE 17              ASEAN POINT OF CARE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS           83

TABLE 18              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY (%)               84

TABLE 19              KEY BUYING CRITERIA, BY TECHNOLOGY                 85

TABLE 20              ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,

2022–2030 (USD MILLION)            90

TABLE 21              DIABETES PREVALENCE (20–79 YRS), DIABETES-RELATED DEATHS, AND PROPORTION OF UNDIAGNOSED DIABETES, BY COUNTRY, 2021   91

TABLE 22              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION) 92

TABLE 23              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)       93

TABLE 24              GLUCOMETERS: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY           94

TABLE 25              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOMETERS, BY COUNTRY, 2022–2030 (USD MILLION)                 95

TABLE 26              GLUCOSE TEST STRIPS: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY  96

TABLE 27              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE TEST STRIPS,

BY COUNTRY, 2022–2030 (USD MILLION)               96

TABLE 28              LANCETS & LANCING DEVICES: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY  97

TABLE 29              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR LANCETS, BY COUNTRY,

2022–2030 (USD MILLION)            98

TABLE 30              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)                99

TABLE 31              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)            100

TABLE 32              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)            101

TABLE 33              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)     101

TABLE 34              TB TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY           102

TABLE 35              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR TB TESTING PRODUCTS,

BY COUNTRY, 2022–2030 (USD MILLION)               103

TABLE 36              INFLUENZA TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY           104

TABLE 37              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 105

TABLE 38              OTHER RESPIRATORY INFECTION TESTING: CURRENTLY AVAILABLE PRODUCTS,

BY COMPANY    106

TABLE 39              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)     107

TABLE 40              MOSQUITO-BORNE DISEASE TESTING: CURRENTLY AVAILABLE PRODUCTS,

BY COMPANY    108

TABLE 41              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)     109

TABLE 42              STD TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY           110

TABLE 43              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS,

BY COUNTRY, 2022–2030 (USD MILLION)               111

TABLE 44              HIV TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY           112

TABLE 45              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,

BY COUNTRY, 2022–2030 (USD MILLION)               113

TABLE 46              HAI TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY           115

TABLE 47              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HAI TESTING PRODUCTS,

BY COUNTRY, 2022–2030 (USD MILLION)               115

TABLE 48              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)            116

TABLE 49              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 117

TABLE 50              HEPATITIS B TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY           118

TABLE 51              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 119

TABLE 52              HEPATITIS C TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY           120

TABLE 53              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 121

TABLE 54              OTHER INFECTIOUS DISEASE TESTING: CURRENTLY AVAILABLE PRODUCTS,

BY COMPANY    122

TABLE 55              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)     123

TABLE 56              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 124

TABLE 57              CARDIOMETABOLIC TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY  125

TABLE 58              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)       127

TABLE 59              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)            127

TABLE 60              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)            129

TABLE 61              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)            130

TABLE 62              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS & ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)     131

TABLE 63              COAGULATION MONITORING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY  132

TABLE 64              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)            133

TABLE 65              PREGNANCY & FERTILITY TESTING: CURRENTLY AVAILABLE PRODUCTS,

BY COMPANY    134

TABLE 66              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)     135

TABLE 67              ASEAN POINT OF CARE DIAGNOSTICS MARKET: TOTAL NUMBER OF PREGNANCIES, BY COUNTRY, 2022−2030 (IN MILLION)     136

TABLE 68              HEMATOLOGY TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY  137

TABLE 69              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)       138

TABLE 70              NUMBER OF CASES FOR TOP FIVE CANCER TYPES, 2022         139

TABLE 71              CANCER MARKER TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY  140

TABLE 72              ASEAN POINT OF CARE DIAGNOSTICS MARKET OF CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)       140

TABLE 73              ESTIMATED NUMBER OF NEW CASES OF COLORECTAL CANCER,

2022 VS. 2035 VS. 2045      142

TABLE 74              FECAL OCCULT BLOOD TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY  142

TABLE 75              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT BLOOD TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)     143

TABLE 76              CHOLESTEROL TESTING PRODUCTS: CURRENTLY AVAILABLE PRODUCTS,

BY COMPANY    144

TABLE 77              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)       145

TABLE 78              URINALYSIS TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY           146

TABLE 79              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION) 147

TABLE 80              DRUGS-OF-ABUSE TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY  148

TABLE 81              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)            149

TABLE 82              OTHER POC PRODUCTS: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY  150

TABLE 83              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,

BY COUNTRY, 2022–2030 (USD MILLION)               150

TABLE 84              ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            152

TABLE 85              BIOCHEMISTRY: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY           153

TABLE 86              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022–2030 (USD MILLION)                 154

TABLE 87              LATERAL FLOW ASSAYS: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY  155

TABLE 88              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR LATERAL FLOW ASSAYS (IMMUNOASSAYS), BY COUNTRY, 2022–2030 (USD MILLION)            156

TABLE 89              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RAPID TESTS

(MOLECULAR DIAGNOSTICS), BY COUNTRY, 2022–2030 (USD MILLION)            158

TABLE 90              ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            160

TABLE 91              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS,

BY COUNTRY, 2022–2030 (USD MILLION)               161

TABLE 92              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,

BY COUNTRY, 2022–2030 (USD MILLION)               163

TABLE 93              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS AND CRITICAL CARE CENTERS, BY COUNTRY, 2022–2030 (USD MILLION)            165

TABLE 94              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR OUTPATIENT SETTINGS AND AMBULATORY CARE CENTERS, BY COUNTRY, 2022–2030 (USD MILLION)         166

TABLE 95              ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2030 (USD MILLION)               167

TABLE 96              ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            171

TABLE 97              INDONESIA: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET      173

TABLE 98              INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,

2022–2030 (USD MILLION)            174

TABLE 99              INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)                 175

TABLE 100            INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)                 175

TABLE 101            INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)         176

TABLE 102            INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)                176

TABLE 103            INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,

2022–2030 (USD MILLION)            176

TABLE 104            INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            177

TABLE 105            INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)                 177

TABLE 106            INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            178

TABLE 107            THAILAND: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET      179

TABLE 108            THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,

2022–2030 (USD MILLION)            180

TABLE 109            THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)                 181

TABLE 110            THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)                 181

TABLE 111            THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)         182

TABLE 112            THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)                182

TABLE 113            THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)                 182

TABLE 114            THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            183

TABLE 115            THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)                 183

TABLE 116            THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            184

TABLE 117            MALAYSIA: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET      186

TABLE 118            MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,

2022–2030 (USD MILLION)            186

TABLE 119            MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)                 187

TABLE 120            MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)                 187

TABLE 121            MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)         188

TABLE 122            MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)                188

TABLE 123            MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)                 188

TABLE 124            MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            189

TABLE 125            MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)                 189

TABLE 126            MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            190

TABLE 127            PHILIPPINES: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET      191

TABLE 128            PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,

2022–2030 (USD MILLION)            192

TABLE 129            PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)                 193

TABLE 130            PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)                 193

TABLE 131            PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)         194

TABLE 132            PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)                194

TABLE 133            PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,

2022–2030 (USD MILLION)            194

TABLE 134            PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            195

TABLE 135            PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)                 195

TABLE 136            PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)            196

TABLE 137            VIETNAM: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET      198

TABLE 138            VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,

2022–2030 (USD MILLION)            198

TABLE 139            VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)                 199

TABLE 140            VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)                 199

TABLE 141            VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)         200

TABLE 142            VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)                200

TABLE 143            VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)                 200

TABLE 144            VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            201

TABLE 145            VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)                 201

TABLE 146            VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)          202

TABLE 147            SINGAPORE: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET      204

TABLE 148            SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,

2022–2030 (USD MILLION)            204

TABLE 149            SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)                 205

TABLE 150            SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)                 205

TABLE 151            SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)         206

TABLE 152            SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)                206

TABLE 153            SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,

2022–2030 (USD MILLION)            206

TABLE 154            SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            207

TABLE 155            SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)                 207

TABLE 156            SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            208

TABLE 157            MYANMAR: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET      210

TABLE 158            MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,

2022–2030 (USD MILLION)            210

TABLE 159            MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)                 211

TABLE 160            MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)                 211

TABLE 161            MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)         212

TABLE 162            MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)                212

TABLE 163            MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)                 212

TABLE 164            MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            213

TABLE 165            MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)                 213

TABLE 166            MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            214

TABLE 167            CAMBODIA: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET      215

TABLE 168            CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,

2022–2030 (USD MILLION)            216

TABLE 169            CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)                 217

TABLE 170            CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)                 217

TABLE 171            CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)         218

TABLE 172            CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)                218

TABLE 173            CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,

2022–2030 (USD MILLION)            218

TABLE 174            CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            219

TABLE 175            CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)                 219

TABLE 176            CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            220

TABLE 177            LAOS: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET                 221

TABLE 178            LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,

2022–2030 (USD MILLION)            222

TABLE 179            LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)             223

TABLE 180            LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)         223

TABLE 181            LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)       224

TABLE 182            LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)            224

TABLE 183            LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)         224

TABLE 184            LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            225

TABLE 185            LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)            225

TABLE 186            LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            226

TABLE 187            BRUNEI: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET                 227

TABLE 188            BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,

2022–2030 (USD MILLION)            228

TABLE 189            BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)             229

TABLE 190            BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)         229

TABLE 191            BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)       230

TABLE 192            BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)            230

TABLE 193            BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)         230

TABLE 194            BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            231

TABLE 195            BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)            231

TABLE 196            BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,

2022–2030 (USD MILLION)            232

TABLE 197            OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN ASEAN POINT OF CARE DIAGNOSTICS MARKET, JANUARY 2021−MARCH 2025       234

TABLE 198            ASEAN POINT OF CARE DIAGNOSTICS MARKET: DEGREE OF COMPETITION         237

TABLE 199            ASEAN POINT OF CARE DIAGNOSTICS MARKET: COUNTRY FOOTPRINT 242

TABLE 200            ASEAN POINT OF CARE DIAGNOSTICS MARKET: PRODUCT FOOTPRINT 243

TABLE 201            ASEAN POINT OF CARE DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT        245

TABLE 202            ASEAN POINT OF CARE DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES             248

TABLE 203            ASEAN POINT OF CARE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY TECHNOLOGY  248

TABLE 204            ASEAN POINT OF CARE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY COUNTRY            249

TABLE 205            ASEAN POINT OF CARE DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2025        251

TABLE 206            ASEAN POINT OF CARE DIAGNOSTICS MARKET: DEALS,

JANUARY 2021–MARCH 2025         252

TABLE 207            ASEAN POINT OF CARE DIAGNOSTICS MARKET: EXPANSIONS,

JANUARY 2021–MARCH 2025         253

TABLE 208            ABBOTT: COMPANY OVERVIEW                254

TABLE 209            ABBOTT: PRODUCTS OFFERED 255

TABLE 210            ABBOTT: PRODUCT APPROVALS, JANUARY 2021–MARCH 2025             258

TABLE 211            ABBOTT: DEALS, JANUARY 2021– MARCH 2025                 258

TABLE 212            F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW          260

TABLE 213            F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED             261

TABLE 214            F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–MARCH 2025         263

TABLE 215            F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021– MARCH 2025        264

TABLE 216            SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW          266

TABLE 217            SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED             267

TABLE 218            SIEMENS HEALTHINEERS AG: PRODUCT APPROVALS,

JANUARY 2021–MARCH 2025         269

TABLE 219            SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021– MARCH 2025            269

TABLE 220            SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021– MARCH 2025        271

TABLE 221            SYSMEX CORPORATION: COMPANY OVERVIEW                 272

TABLE 222            SYSMEX CORPORATION: PRODUCTS OFFERED                 273

TABLE 223            SYSMEX CORPORATION: EXPANSIONS, JANUARY 2021−MARCH 2025       274

TABLE 224            DANAHER CORPORATION: COMPANY OVERVIEW          276

TABLE 225            DANAHER CORPORATION: PRODUCTS OFFERED             277

TABLE 226            BD: COMPANY OVERVIEW           280

TABLE 227            BD: PRODUCTS OFFERED            281

TABLE 228            BD: DEALS, JANUARY 2021–MARCH 2025 282

TABLE 229            BD: EXPANSIONS, JANUARY 2021–MARCH 2025                 282

TABLE 230            QUIDELORTHO CORPORATION: COMPANY OVERVIEW          283

TABLE 231            QUIDELORTHO CORPORATION: PRODUCTS OFFERED             284

TABLE 232            QUIDELORTHO CORPORATION: PRODUCT APPROVALS,

JANUARY 2021–MARCH 2025         287

TABLE 233            QUIDELORTHO CORPORATION: DEALS, JANUARY 2021–MARCH 2025         288

TABLE 234            QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2021–MARCH 2025         290

TABLE 235            CARDINAL HEALTH: COMPANY OVERVIEW                 291

TABLE 236            CARDINAL HEALTH: PRODUCTS OFFERED                 292

TABLE 237            CARDINAL HEALTH: DEALS, JANUARY 2021–MARCH 2025       293

TABLE 238            CARDINAL HEALTH: EXPANSIONS, JANUARY 2021–MARCH 2025             294

TABLE 239            BIOMÉRIEUX: COMPANY OVERVIEW      295

TABLE 240            BIOMÉRIEUX: PRODUCTS OFFERED       296

TABLE 241            BIOMÉRIEUX: PRODUCT APPROVALS, JANUARY 2021–MARCH 2025             297

TABLE 242            BIOMÉRIEUX: DEALS, JANUARY 2021–MARCH 2025        298

TABLE 243            EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW          299

TABLE 244            EKF DIAGNOSTICS HOLDINGS PLC: PRODUCTS OFFERED             300

TABLE 245            EKF DIAGNOSTICS HOLDINGS PLC: PRODUCT LAUNCHES,

JANUARY 2021–MARCH 2025         301

TABLE 246            EKF DIAGNOSTICS HOLDINGS PLC: DEALS, JANUARY 2021–MARCH 2025         301

TABLE 247            EKF DIAGNOSTICS HOLDINGS PLC: EXPANSIONS, JANUARY 2021–MARCH 2025            301

TABLE 248            THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW          302

TABLE 249            THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED             303

TABLE 250            THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES,

JANUARY 2021–MARCH 2025         304

TABLE 251            THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–MARCH 2025         304

TABLE 252            ACCUBIOTECH CO., LTD.: COMPANY OVERVIEW          305

TABLE 253            ACCUBIOTECH CO., LTD.: PRODUCTS OFFERED                 305

TABLE 254            ACCUBIOTECH CO., LTD.: PRODUCT APPROVALS, JANUARY 2021–MARCH 2025              307

TABLE 255            BIOSYNEX SA: COMPANY OVERVIEW      308

TABLE 256            SD BIOSENSOR, INC.: COMPANY OVERVIEW                 309

TABLE 257            SEKISUI DIAGNOSTICS: COMPANY OVERVIEW                 311

TABLE 258            WERFEN: COMPANY OVERVIEW                312

TABLE 259            TRINITY BIOTECH: COMPANY OVERVIEW                 313

TABLE 260            PTS DIAGNOSTICS: COMPANY OVERVIEW                 314

TABLE 261            LIFESCAN IP HOLDINGS, LLC: COMPANY OVERVIEW          315

TABLE 262            CTK BIOTECH, INC.: COMPANY OVERVIEW                 316

TABLE 263            WONDFO: COMPANY OVERVIEW              318

TABLE 264            ARKRAY, INC.: COMPANY OVERVIEW     319

TABLE 265            XIAMEN BOSON BIOTECH CO., LTD.: COMPANY OVERVIEW          320

TABLE 266            CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD.: COMPANY OVERVIEW   322

TABLE 267            ANBIO BIOTECHNOLOGY INC.: COMPANY OVERVIEW          323

TABLE 268            SG DIAGNOSTICS: COMPANY OVERVIEW                 325

LIST OF FIGURES

FIGURE 1              MARKETS COVERED & REGIONS CONSIDERED                 28

FIGURE 2              ASEAN POINT OF CARE DIAGNOSTICS MARKET: RESEARCH DESIGN         32

FIGURE 3              ASEAN POINT OF CARE DIAGNOSTICS MARKET: KEY INDUSTRY INSIGHTS             37

FIGURE 4              BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS     37

FIGURE 5              BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE AND DESIGNATION     38

FIGURE 6              BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH              39

FIGURE 7              CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS                 40

FIGURE 8              ASEAN POINT OF CARE DIAGNOSTICS MARKET: TOP-DOWN APPROACH                41

FIGURE 9              ASEAN POINT OF CARE DIAGNOSTICS MARKET: DATA TRIANGULATION METHODOLOGY            42

FIGURE 10            ASEAN POINT OF CARE DIAGNOSTICS MARKET: RESEARCH ASSUMPTIONS           43

FIGURE 11            ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT,

2025 VS. 2030 (USD MILLION)      45

FIGURE 12            ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY,

2025 VS. 2030 (USD MILLION)      46

FIGURE 13            ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER,

2025 VS. 2030 (USD MILLION)      47

FIGURE 14            ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY,

2025 VS. 2030 (USD MILLION)      48

FIGURE 15            RISING PREVALENCE OF INFECTIOUS DISEASES TO PROPEL MARKET      49

FIGURE 16            GLUCOSE MONITORING PRODUCTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD    50

FIGURE 17            BIOCHEMISTRY SEGMENT TO HOLD LARGEST MARKET SHARE TILL 2030            50

FIGURE 18            HOME CARE SETTINGS AND CLINICAL LABORATORIES TO ACCOUNT FOR MAJOR MARKET SHARES DURING FORECAST PERIOD       51

FIGURE 19            VIETNAM TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD       51

FIGURE 20            ASEAN POINT OF CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES                 52

FIGURE 21            ESTIMATES OF TB INCIDENCE FOR SOUTHEAST ASIA REGION,

BY AGE GROUP AND GENDER (2023)       54

FIGURE 22            ASEAN POINT OF CARE DIAGNOSTICS MARKET: TRENDS/DISRUPTIONS

IMPACTING CUSTOMERS’ BUSINESSES 62

FIGURE 23            ASEAN POINT OF CARE DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS               64

FIGURE 24            ASEAN POINT OF CARE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS             65

FIGURE 25            ASEAN POINT OF CARE DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS  67

FIGURE 26            INVESTMENT & FUNDING SCENARIO, 2021−2024            68

FIGURE 27            ASEAN POINT OF CARE DIAGNOSTICS MARKET: PATENT ANALYSIS,

JANUARY 2014–DECEMBER 2024 71

FIGURE 28            ASEAN POINT OF CARE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS           82

FIGURE 29            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY       84

FIGURE 30            KEY BUYING CRITERIA, BY TECHNOLOGY                 85

FIGURE 31            ASEAN POINT OF CARE DIAGNOSTICS MARKET: POTENTIAL OF AI            86

FIGURE 32            ASEAN: POINT OF CARE DIAGNOSTICS MARKET SNAPSHOT          170

FIGURE 33            REVENUE ANALYSIS OF KEY PLAYERS IN ASEAN POINT OF CARE

DIAGNOSTICS MARKET, 2022–2024            236

FIGURE 34            MARKET SHARE ANALYSIS OF KEY PLAYERS IN ASEAN POINT OF CARE DIAGNOSTICS MARKET, 2024     237

FIGURE 35            ASEAN POINT OF CARE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024  240

FIGURE 36            ASEAN POINT OF CARE DIAGNOSTICS MARKET: COMPANY FOOTPRINT 241

FIGURE 37            ASEAN POINT OF CARE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024                 247

FIGURE 38            EV/EBITDA OF KEY VENDORS, 2025         249

FIGURE 39            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025            250

FIGURE 40            ASEAN POINT OF CARE DIAGNOSTICS MARKET: BRAND/PRODUCT

COMPARISON MATRIX  250

FIGURE 41            ABBOTT: COMPANY SNAPSHOT (2024)  255

FIGURE 42            F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)             261

FIGURE 43            SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)             267

FIGURE 44            SYSMEX CORPORATION: COMPANY SNAPSHOT (2023)    273

FIGURE 45            DANAHER CORPORATION: COMPANY SNAPSHOT (2024)             277

FIGURE 46            BD: COMPANY SNAPSHOT (2024)              281

FIGURE 47            QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2024)             284

FIGURE 48            CARDINAL HEALTH: COMPANY SNAPSHOT (2024)    292

FIGURE 49            BIOMÉRIEUX: COMPANY SNAPSHOT (2024)                 296

FIGURE 50            EKF DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2023)             300

FIGURE 51            THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)             303